We recently described a selective metabolic vulnerability in non-small-cell lung cancer (NSCLC) cells, whereby co-occurring mutations in the KRAS oncogene and LKB1 tumour-suppressor result in cellular addiction to lysosomal catabolism for maintenance of mitochondrial health33. Here, KRAS is linked to neoplasm.